Nascent Biotech
Pre-clinicalNascent Biotech is the home of the natural human antibody cancer product Pritimumab, which has been shown to fight rare forms of cancer successfully.
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $15M
About
Nascent Biotech is the home of the natural human antibody cancer product Pritimumab, which has been shown to fight rare forms of cancer successfully.
AntibodiesBiologics
Funding History
2Total raised:$15M
Series A$12MApr 15, 2023
Seed$3MNov 15, 2021